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INTRODUCTION  
 Febuxostat chemically is 2- [3- cyano-4- (2- 
methlypropoxy) phenyl] - 4- methlythiazole- 5 -carboxylic 
acid
1
 (Figure 1). It is a non purine selective inhib itor of 
xanthine oxidase that is indicated for use in the treatment 
of hyperuricemia and gout. In contrast to allopurinol, 
febuxostat inhibits both oxidized and reduced forms of 
xanthine oxidase and has min imal effects on other 
enzymes of purine and pyrimid ine metabolis m 3, 4. A  
study comparing febuxostat to allopurinol found that more 
individuals treated with febuxostat had decreased levels of 
uric acid, but there was no difference in the amount of 
initial gout flares or the surface area of gout tophi
2
. 
Ketorolac tromethamine  
Systematic (IUPAC) name: (±)-5-benzoyl-2, 3- dihydro-
1H-pyrrolizine-1-carboxylic acid, 2- amino-2 
(hydroxymethyl)-1, 3-propanediol
1, 3
 (Figure 2). 
 
Figure 1: Chemical structure of Febuxostat 
Ketorolac tromethamine (Brand name Toradol and 
Acular) is a non-steroidal anti-inflammatory drug (NSAID) 
in the family of heterocyclic acetic acid derivative, often 
used as an analgesic, antipyretic and anti -inflammatory. 
 
Figure 2: Chemical structure of Keterolac 
Ketorolac acts by inhibiting the bodily synthesis of 
prostagladins. Both Febuxostat and Ketorolac have been 
analyzed by various techniques either alone or in  
combination with other drugs. Several methods have been 
applied to determine Febuxostat involving 
spectrophotometry
4
, HPLC 
5,
 LC/MS
6
. 
Literature review revealed different analytical methods 
such as UV Method
7
, HPLC
8-11 
and HPTLC
12-13
 for the 
quantitative determination of Ketorolac. The present work 
deals with analytical evaluation of ketorolac in tablets by 
HPLC
14
 using UV-VIS Detector. The main objective of the 
work was to develop simple, fast, sensitive and accurate 
method. 
In this paper we reported a sensitive liquid  
chromatographic method with wide linearity range, good 
resolution where running time is less than 10 mins. The 
method has been validated as per the ICH guidelines 
15-16
 
and can be successfully applied to pharmaceutical 
formulat ions. 
 
ABSTRACT 
A simple, fast, precise, selective and accurate RP-HPLC method was developed and validated for the simultaneous 
determination of Febuxostat and Ketorolac from bulk and formulations. Chromatographic separation was achieved isocratically 
on a Waters C18 column (250×4.6 mm, 5 µ particle size) using a mobile phase, Methanol and Ammonium acetate buffer 
(adjusted to pH 6.0 with 1% orthophosphoric acid) in the ratio of 60:40. The flow rate was 1 ml/min and effluent was detected 
at 321nm. The retention time of Febuxostat and Ketorolac were 2.62 min and 3.96 min. respectively. Linearity was observed in 
the concentration range of 5-30µg/ml and 10-60 µg/ml for Febuxostat and Ketorolac respectively with correlation coefficient 
0.999 for both the drugs. Percent recoveries obtained for both the drugs were 99.94-99.22% and 99.44-101.06%, respectively. 
The method was validated according to the ICH guidelines with respect to specificity, linearity, accuracy, precision and 
robustness. The method developed can be used for the routine analysis of Febuxostat and Ketorolac from their combined dosage 
form. 
Key words: RP-HPLC Method; UV-VIS detection; Febuxostat and Keterolac; Tablet dosage forms. 
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MATERIALS AND METHODS  
Reagents and chemicals  
Methanol HPLC grade was procured from E.Merck Ltd, 
Mumbai. Methanol, orthophosphoric acid, Ammonium 
acetate buffer AR grade were procured from S.D. fine 
chemicals, Hyderabad. Water HPLC grade was  prepared 
using Millipore purification system. Febuxostat and 
Keterolac reference standards procured from Dr.Reddy’s  
laboratories, Hyderabad. 
Instrumentation 
The HPLC system consists of water Empower 2487 having 
photodiode array detector system, which was connected 
with the help of Empower-2 software for data integration 
and processing. Inertsil ODS‐3V (250 X 4.6 mm) 5μ 
column was used for the analysis.  
HPLC conditions 
 The contents of the mobile phase were Methanol and 
Ammonium acetate buffer (adjusted to pH 6.0 with 1% 
orthophosphoric acid) in the ratio of 60:40. These were 
filtered through 0.45μ membrane filter and degassed by 
sonication before use. The flow rate of mobile phase was 
optimized to 1.0 ml / min. The run time was set at 10 min  
and column temperature was maintained at ambient. The 
volume of in jection was 10μl, and the eluent was detected 
at 321nm. Each of standard and test preparations was 
injected into the column and the responses recorded 
(Figure 3 and 4). 
METHOD  
The RP-HPLC Method of Febuxostat and Ketorolac were 
achieved by isocratic elution technique with UV –VIS 
Detector.  FBT and KTC were determined at 321nm   
respectively with the concentration range of 5-30 g/ml for 
FBT and 10-60 g/ml fo r KTC respectively.fig.03 &04.  
For analysis of tablet formulat ion, the tablet powder 
equivalent to 25 mg was taken, dissolved in 25 ml 
volumetric flask and made up to 25ml with Methanol. The 
solution was sonicated for 15min, centrifuged at 100 rpm 
for 15 min and filtered through Whatmann filter paper 
No.41. From clear solution, further dilutions were made to 
get 10 g/ml of FBT and KTC theoretically.  
Preparation of standard stock solution 
Standard stock solutions Febuxostat and Ketorolac of 
strength 1mg/ml were prepared using dichloromethane. 
Appropriate amounts of these stock solutions were then 
further diluted to get the required concentrations of 
standard stock solutions. 
Table 1: It shows system suitability parameters  
Parameters  Febuxostat Keterolac  
Theoretical plates 34075.88  15192.87 
Asymmetry Factor 1.05 1.15 
HETP (cm) 0.00075 0.00162 
Resolution*  4.63 
 
System suitability studies 
The resolution, number of theoretical plates, retention time 
and peak asymmetry were calculated for the working 
standard solutions and is as shown in Table 1.  
The values obtained demonstrated the suitability of the 
system for the analysis of these drugs in combination. The 
typical chromatogram of standard solution is as shown in 
Figure 3. 
 
Figure 3: Typical chromatogram of Febuxostat and 
Keterolac  
 
Figure 4: Typical chromatograms for recovery studies  
ASSAY 
Preparation of sample solutions 
Twenty tablets were weighed and powdered. Powder 
equivalent to 10 mg of Febuxostat was weighed and 
transferred to 10 ml volumetric flask. Keterolac about 8 ml 
was added and sonicated for 10 min, volume was made up 
with the same solvent. This solution was then filtered  
through membrane filter paper. Further d ilutions were 
made in dichloromethane to get concentrations in Beers 
law range. The retention times of Febuxostat and 
Ketorolac were found to be 2.62 ± 0.02 and 3.96 ± 0.03 
respectively. The assay was calculated from the equation 
of regression line for each drug. The percentage assay of 
individual d rug was calculated and presented in Table 2.  
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Table 2: It shows assay of tablet 
Drug  Amount Present (mg/tab) Amount Found ((mg/tab) %   Label Claim 
Febuxostat  Furic® Tablets 40 39.23 98.075 
Keterolac  15 14.97 99.08 
 
 
Figure 3: Calibration Graph of Febuxostat  
 
Figure 4: Calibration Graph of Keterolac  
For recovery studies, to the reanalyzed formulation, 
solutions of raw material containing different 
concentrations were added and the amount of drug 
recovered was calculated. 
The procedure was repeated as per the analysis of 
formulat ion. The amount of drug recovered was calculated 
by using slope and intercept values from the calibrat ion 
graph. Finally the method was validated as per ICH guide 
lines
 
for precision, accuracy, specificity, linearity, 
reproducibility, limit of detection and limit of 
quantification.  
METHOD VALIDATION 
As per ICH guidelines, the method validation parameters 
checked were specificity, linearity, precision, accuracy, 
limit  of detection, limit of quantitation and robustness. 
Specificity 
A blank solution (mobile phase) was injected and the 
chromatogram showed no inferring peaks at retention time 
of the two drugs. The chromatogram of Febuxostat and 
Ketorolac extracted from the tablet were compared with 
those acquired from Febuxostat and Ketorolac standards, 
correlation was good (in terms of tR and area) indicates 
specificity of method. Common tablet excip ients like 
starch, lactose, magnesium stearate were dispers ed in 
dichloromethane, filtered and in jected. There was no 
interference found. 
 
Linearity and range 
Aliquots of standard stock solutions of Febuxostat and 
Ketorolac were taken in 10 ml volumetric flasks and 
diluted with dichloromethane to get final concentrations in 
range of 5-30μg/ml for Febuxostat and 10-60μg/ml for 
Ketorolac. Triplicate in jections were made five t imes for 
each concentration for each drug separately and chromato 
graphed under the conditions as described above. The plots 
of peak area versus respective concentrations of 
Febuxostat and Ketorolac were found to be linear in the 
concentration range of 5-30μg/ml and 10-60μg/ml 
respectively. The linear regression equations of the lines 
are: 
For Febuxostat -y = 48266x + 491236, (r2 = 0.9996) 
For Ketorolac -y = 82864x + 163170, (r2 = 0.9993) 
Precision 
Precision study was performed to find out intra-day and 
inter-day variations. The percent relative standard 
deviation for intra-day precision was 0.288% for 
Febuxostat and 0.232% for and Ketorolac and inter-day 
precision was 1.137% for Febuxostat and 1.323% for 
Ketorolac. Both the values were well within the limit of 
2% as per ICH guidelines. 
Accuracy 
The accuracy was determined by recovery studies. The 
recovery studies were performed by standard addition 
method, at 80%, 100%, 120% level. Percent recovered was 
calculated using regression equation. For both the drugs, 
recovery was performed in same way and in triplicate. The 
percentage recovery were calculated and presented in 
Table 3. 
Limit of detection and limit of quantitation 
The limit of detection (LOD) is the smallest concentration 
that can be detected but not necessarily quantified as an 
exact value.  
     LOD =     3.3 X Standard deviation of y intercept 
Slope of calib ration curve 
Febuxostat - 1.13μg/ml 
Keterolac - 0.23μg/ml 
 
The LOQ is the lowest amount of analyte in the sample 
that can be quantitatively determined with suitable 
precision and accuracy. 
LOQ =       10 X Standard deviation of y intercept 
                           Slope of calib ration curve 
Febuxostat - 3.03μg/ml 
Keterolac - 0.87μg/ml 
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Robustness 
Robustness of the method was determined by making 
slight deliberate changes in chromatographic conditions 
like 1% change in ratio of mobile phase constituents, ± 
1nm change in detection wavelength and 0.05% change in 
flow rate. It was observed that there were no marked  
changes in the chromatogram. It suggests that the 
developed method is robust. 
RES ULTS AND DISCUSS ION  
The proposed method was found to be simple and sensitive 
with linearity in the concentration range of 5 to 30μg/ml 
for Febuxostat and 10 to 60μg/ml for Ketorolac. The 
method was found to be accurate and precise as indicated 
by results of recovery studies and %RSD not more than 
2%. LOD and LOQ for Febuxostat were found to be 
0.23μg/ml and 0.87μg/ml respectively and for Ketorolac 
were 1.13μg/ml and 3.03μg/ml respectively. The proposed 
method was found to be specific as there is no interference 
from common tablet excip ients like lactose, starch etc. 
Table 3: Recovery Studies  
 
CONCLUS ION 
The results of the analysis of pharmaceutical dosage forms by the proposed methods are highly reproducible, reliable, and 
are in good agreement with the label claims of the drug. The additives usually present in the pharmaceutical formulations 
of the assayed samples did not interfere with Febuxostat and Ketorolac. It may be said that the proposed methods are 
precise, sensitive, and accurate, so that these can be used as standard pharmacopoeial methods for the simultaneous 
determination of Febuxostat and Ketorolac in tablets using the HPLC systems. The advantages of the proposed method 
involve a simple procedure for sample preparation and relatively short time of analysis. Apart from this, it can be used for 
assays of Febuxostat and Ketorolac in bio logical fluids or in pharmacokinetic investigations. 
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Drug Sample No. Amount % ( g/ml ) Amount added ( g/ml ) % Recovery* S .D % R.S.D 
FBT 1 
2 
3 
15.0235 
15.0235 
15.0235 
5.00 
10.00 
15.00 
97.94 
98.71 
99.22 
0.6433 0.6533 
KTC 1 
2 
3 
30.0431 
30.0431 
30.0431 
10.00 
20.00 
30.00 
100.66 
99.44 
101.06 
0.8438 0.8406 
